Shield Therapeutics : First signs of hoped-for Accrufer Rx inflection
Shield Therapeutics' recent Q2 trading update showed some early signs of the hoped for upward inflection in the US Accrufer (ferrric maltol) trajectory, as the joint marketing operation with Viatris became operational over the period. Key performance indicators reported included US prescription volShield Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of late stage, hospital-focused pharmaceuticals which address areas of high unmet medical need. Co.'s key products are Feraccru®, commercially available for the treatment of Iron Deficiency Anaemia, and PT20, for the treatment of systemic phosphate accumulation (otherwise known as hyperphosphatemia). Co. has an additional pipeline of three prescription pharmaceutical assets (PT20, PT30 and PT40) with commercial synergies.
Capital Network is the foremost authority on utilising digitisation to allow companies to achieve their corporate goals, whether those goals pertain to raising capital, increasing investor awareness, boosting liquidity or allowing the business to flourish. We are proud to deliver bespoke, industry-leading services to a broad range of capital market clients. To deliver on our range of digitised services clients are assigned tier-1 analysts who have extensive sector knowledge, numerous accreditations and a track record of delivering success.
The investor community is evolving and we allow investment banks, fund managers, hedge funds, wealth managers, trusts, family offices and private investors the capacity to access new investment ideas as well delivering further insight into their current portfolio. In addition to driving value for our diverse client base, we empower investors with our digital solutions.
Our approach to serving clients takes a traditional method of doing first-class business in a first-class way, in conjunction with implementing the most technologically advanced services for them. We strive to build trusted, long-term relationships built on diligence and foresight, and identifying ways to help clients achieve their most important business objectives.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.